Bone marrow transplant rejection treatment market is anticipated to grow at a significant CAGR during the forecast period. Bone marrow transplantation is a therapy to replace diseased bone marrow cells with healthy ones from a donor and it is done through either blood stem cells or by donating certain specific types of white blood cells. However, the rejection occurs when the transplanted immune system fails to accept the donated tissue. It is also known as graft-versus-host disease (GVHD). The major factor contributing to the growth of the global bone marrow transplant rejection treatment market is the increasing demand for better treatment options with minimal side effects across the globe.
Moreover, the market is also growing due to the increasing prevalence of leukemia and lymphoma globally. According to the Leukemia and Lymphoma Society, every 3 minutes, one person is diagnosed with leukemia, lymphoma or myeloma in the US. Additionally, in 2021, an estimated 186,400 people are anticipated to be diagnosed with leukemia, lymphoma or myeloma in the US. Furthermore, in 2021 new cases of leukemia, lymphoma and myeloma are anticipated to account for 9.8% of the estimated 1,898,160 new cancer cases that will be diagnosed in the US.
Some major key players in the market include Merck & Co., Inc., and Bristol-Myers Squibb Co., among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in December 2021, The US FDA approved Bristol Myers Squibb’s Orencia (abatacept) for the prophylaxis (prevention) of acute graft versus host disease (aGVHD). Orencia originally approved by the FDA in 2005 for treating adult rheumatoid arthritis and also approved for treating polyarticular juvenile idiopathic arthritis and adult psoriatic arthritis. It may now be used in adults and pediatric patients two years of age or older undergoing hematopoietic stem cell transplantation (commonly known as bone marrow transplantation or stem cell transplantation) from an unrelated donor.
To Request a Sample of our Report on Bone Marrow Transplant Rejection Treatment Market: https://www.omrglobal.com/request-sample/bone-marrow-transplant-rejection-treatment-market
Market Coverage
- The market number available for – 2021-2029
- Base year- 2021
- Forecast period- 2023-2029
Segment Covered-
- By Product Type
- By Application
Regions Covered-
- North America
- Europe
- Asia-Pacific
- Rest of the World
Competitive Landscape- Merck & Co., Inc., and Bristol-Myers Squibb Co., among others.
Bone Marrow Transplant Rejection Treatment Market Report by Segment
By Type
- Azathioprine
- Adrenocorticotropic Hormone
- Cyclophosphamide
- Cyclosporine A
- Others
By Application
- Clinic
- Hospital
- Others
A full Report of Bone Marrow Transplant Rejection Treatment Market is Available @ https://www.omrglobal.com/industry-reports/bone-marrow-transplant-rejection-treatment-market
Bone Marrow Transplant Rejection Treatment Market Report by Region
North America
- United States
- Canada
Europe
- UK
- Germany
- Spain
- France
- Italy
- Rest of Europe
Asia-Pacific
- India
- China
- Japan
- South Korea
- Rest of APAC
Rest of the World
- Latin America
- Middle East & Africa
Reasons to buy from us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404
